Literature DB >> 20031193

Spermidine/spermine N1-acetyltranferase modulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistant human ovarian cancer cell lines.

Gaetano Marverti1, Alessio Ligabue, Davide Guerrieri, Giuseppe Paglietti, Sandra Piras, Maria P Costi, Davide Farina, Chiara Frassineti, Maria G Monti, Maria S Moruzzi.   

Abstract

OBJECTIVE: Polyamines have been shown to play a role in the growth and survival of several solid tumors, including ovarian cancer. Intracellular polyamine depletion by the inhibition of biosynthesis enzymes or by the induction of the catabolic pathway leads to antiproliferative effects in many different tumor cell lines. Recent studies showed that the thymidylate synthase inhibitor 5-fluorouracil (5-FU) affects polyamine metabolism in colon carcinoma cells through the induction of the key catabolic enzyme spermidine/spermine N1-acetyltransferase (SSAT).
METHODS: We therefore examined whether combinations of novel folate cycle inhibitors with quinoxaline structure and drugs that specifically target polyamine metabolism, such as diethylderivatives of norspermine (DENSPM) or spermine (BESpm), have synergistic effect in killing cisplatin-sensitive and drug-resistant daughter human ovarian cell lines.
RESULTS: Our results showed that simultaneous drug combination or quinoxaline pre-treatment synergistically increased SSAT expression, depleted polyamines, increased reactive oxygen species production, and produced synergistic tumor cell killing in both cell lines. Of note, this combined therapy increased the chemosensitivity of cisplatin-resistant cells and cross-resistant to the polyamine analogues. On the contrary, some pre-treatment regimens of Spm analogues were antagonistic.
CONCLUSIONS: These results show that SSAT plays an important role in novel folate cycle inhibitors effects and suggest that their combination with analogues has potential for development as therapy for ovarian carcinoma based on SSAT modulation. Copyright (c) 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20031193     DOI: 10.1016/j.ygyno.2009.11.030

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Structural Bases for the Synergistic Inhibition of Human Thymidylate Synthase and Ovarian Cancer Cell Growth by Drug Combinations.

Authors:  Cecilia Pozzi; Matteo Santucci; Gaetano Marverti; Domenico D'Arca; Lorenzo Tagliazucchi; Stefania Ferrari; Gaia Gozzi; Lorena Losi; Giusy Tassone; Stefano Mangani; Glauco Ponterini; Maria Paola Costi
Journal:  Cancers (Basel)       Date:  2021-04-24       Impact factor: 6.639

2.  Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression.

Authors:  Alessio Ligabue; Gaetano Marverti; Ursula Liebl; Hannu Myllykallio
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

3.  A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells.

Authors:  Gaetano Marverti; Gaia Gozzi; Eleonora Maretti; Angela Lauriola; Leda Severi; Francesca Sacchetti; Lorena Losi; Salvatore Pacifico; Stefania Ferrari; Glauco Ponterini; Eliana Leo; Maria Paola Costi; Domenico D'Arca
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

4.  Folic Acid-Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting.

Authors:  Gaetano Marverti; Chiara Marraccini; Andrea Martello; Domenico D'Arca; Salvatore Pacifico; Remo Guerrini; Francesca Spyrakis; Gaia Gozzi; Angela Lauriola; Matteo Santucci; Giuseppe Cannazza; Lorenzo Tagliazucchi; Addolorata Stefania Cazzato; Lorena Losi; Stefania Ferrari; Glauco Ponterini; Maria P Costi
Journal:  J Med Chem       Date:  2021-03-12       Impact factor: 7.446

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.